Progress in reducing the global impact of cancer is slow, but the Galleri blood test, developed by the American company Grail, has sparked hope. It can detect signals from 50 types of cancer, with a correct identification rate of 62% for individuals with positive results and a specificity of 99.6% for those without cancer. However, 38% of positive results are false alarms, and the sensitivity of the test is only 40.4%, meaning that many cases of cancer could be missed. Although the test could become a useful tool in future screening programs, its high cost and the lack of evidence that its widespread use reduces cancer mortality are important considerations. In conclusion, although preliminary data is promising, the Galleri test is not a complete solution.
Sources
Latest News
12:45
The Competition Council fined 21 companies 83.2 million lei for anti-competitive agreements in the field of seeds and plant protection products.
12:43
Dumitru 'Mitică' Marcu, former footballer of Universitatea Craiova and Steaua București, passed away at the age of 76.
12:43
Explosion followed by fire in Arad: one person was injured
12:31
The extradition of Paul Philip of Romania is postponed after his lawyers cited heart problems.
12:25
The nuclear power plant in Cernavodă has been shut down / The first effects of disconnecting reactor 2
See more news